Neovasc Inc.
Neovasc Inc. NVCN Peers
See (NVCN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVCN | $30.03 | N/A | 82.86M | -1.99 | -$15.07 | N/A |
| ABT | $129.02 | -2.25% | 224.47B | 16.76 | $7.70 | +1.76% |
| BSX-PA | $122.18 | +2.37% | 175.45B | 230.53 | $0.53 | N/A |
| BSX | $102.97 | +0.10% | 152.34B | 75.16 | $1.37 | N/A |
| SYK | $387.47 | -0.16% | 148.08B | 52.29 | $7.41 | +0.84% |
| MDT | $85.06 | -0.87% | 109.09B | 25.93 | $3.28 | +3.27% |
| EW | $75.48 | +0.91% | 44.28B | 31.19 | $2.42 | N/A |
| DXCM | $84.11 | -1.11% | 32.98B | 63.24 | $1.33 | N/A |
| STE | $231.16 | -0.83% | 22.71B | 37.22 | $6.21 | +0.96% |
| PHG | $24.22 | -3.27% | 22.40B | 83.52 | $0.29 | +3.11% |
Stock Comparison
NVCN vs ABT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ABT has a market cap of 224.47B. Regarding current trading prices, NVCN is priced at $30.03, while ABT trades at $129.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ABT's P/E ratio is 16.76. In terms of profitability, NVCN's ROE is -1.21%, compared to ABT's ROE of +0.24%. Regarding short-term risk, NVCN is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BSX-PA Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, NVCN is priced at $30.03, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NVCN's ROE is -1.21%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, NVCN is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BSX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BSX has a market cap of 152.34B. Regarding current trading prices, NVCN is priced at $30.03, while BSX trades at $102.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BSX's P/E ratio is 75.16. In terms of profitability, NVCN's ROE is -1.21%, compared to BSX's ROE of +0.10%. Regarding short-term risk, NVCN is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs SYK Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SYK has a market cap of 148.08B. Regarding current trading prices, NVCN is priced at $30.03, while SYK trades at $387.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SYK's P/E ratio is 52.29. In terms of profitability, NVCN's ROE is -1.21%, compared to SYK's ROE of +0.11%. Regarding short-term risk, NVCN is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs MDT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, MDT has a market cap of 109.09B. Regarding current trading prices, NVCN is priced at $30.03, while MDT trades at $85.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas MDT's P/E ratio is 25.93. In terms of profitability, NVCN's ROE is -1.21%, compared to MDT's ROE of +0.09%. Regarding short-term risk, NVCN is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs EW Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, EW has a market cap of 44.28B. Regarding current trading prices, NVCN is priced at $30.03, while EW trades at $75.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas EW's P/E ratio is 31.19. In terms of profitability, NVCN's ROE is -1.21%, compared to EW's ROE of +0.49%. Regarding short-term risk, NVCN is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs DXCM Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, DXCM has a market cap of 32.98B. Regarding current trading prices, NVCN is priced at $30.03, while DXCM trades at $84.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas DXCM's P/E ratio is 63.24. In terms of profitability, NVCN's ROE is -1.21%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, NVCN is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs STE Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, STE has a market cap of 22.71B. Regarding current trading prices, NVCN is priced at $30.03, while STE trades at $231.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas STE's P/E ratio is 37.22. In terms of profitability, NVCN's ROE is -1.21%, compared to STE's ROE of +0.07%. Regarding short-term risk, NVCN is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs PHG Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, PHG has a market cap of 22.40B. Regarding current trading prices, NVCN is priced at $30.03, while PHG trades at $24.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas PHG's P/E ratio is 83.52. In terms of profitability, NVCN's ROE is -1.21%, compared to PHG's ROE of -0.06%. Regarding short-term risk, NVCN is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs PODD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, PODD has a market cap of 22.13B. Regarding current trading prices, NVCN is priced at $30.03, while PODD trades at $314.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas PODD's P/E ratio is 54.31. In terms of profitability, NVCN's ROE is -1.21%, compared to PODD's ROE of +0.41%. Regarding short-term risk, NVCN is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ZBH Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ZBH has a market cap of 19.26B. Regarding current trading prices, NVCN is priced at $30.03, while ZBH trades at $97.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ZBH's P/E ratio is 21.64. In terms of profitability, NVCN's ROE is -1.21%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NVCN is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs ABMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, NVCN is priced at $30.03, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NVCN's ROE is -1.21%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NVCN is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs ALGN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ALGN has a market cap of 13.80B. Regarding current trading prices, NVCN is priced at $30.03, while ALGN trades at $190.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ALGN's P/E ratio is 34.68. In terms of profitability, NVCN's ROE is -1.21%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NVCN is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs SWAV Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SWAV has a market cap of 12.57B. Regarding current trading prices, NVCN is priced at $30.03, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NVCN's ROE is -1.21%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NVCN is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs SNN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SNN has a market cap of 12.36B. Regarding current trading prices, NVCN is priced at $30.03, while SNN trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SNN's P/E ratio is 30.05. In terms of profitability, NVCN's ROE is -1.21%, compared to SNN's ROE of +0.08%. Regarding short-term risk, NVCN is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs PEN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, PEN has a market cap of 11.46B. Regarding current trading prices, NVCN is priced at $30.03, while PEN trades at $295.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas PEN's P/E ratio is 276.47. In terms of profitability, NVCN's ROE is -1.21%, compared to PEN's ROE of +0.04%. Regarding short-term risk, NVCN is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs GMED Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, GMED has a market cap of 7.88B. Regarding current trading prices, NVCN is priced at $30.03, while GMED trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas GMED's P/E ratio is 77.64. In terms of profitability, NVCN's ROE is -1.21%, compared to GMED's ROE of +0.05%. Regarding short-term risk, NVCN is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BIO Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BIO has a market cap of 6.87B. Regarding current trading prices, NVCN is priced at $30.03, while BIO trades at $253.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BIO's P/E ratio is -3.31. In terms of profitability, NVCN's ROE is -1.21%, compared to BIO's ROE of -0.32%. Regarding short-term risk, NVCN is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BIO-B Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BIO-B has a market cap of 6.74B. Regarding current trading prices, NVCN is priced at $30.03, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, NVCN's ROE is -1.21%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, NVCN is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs BRKR Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BRKR has a market cap of 5.87B. Regarding current trading prices, NVCN is priced at $30.03, while BRKR trades at $38.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BRKR's P/E ratio is 74.50. In terms of profitability, NVCN's ROE is -1.21%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, NVCN is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs GKOS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, GKOS has a market cap of 5.27B. Regarding current trading prices, NVCN is priced at $30.03, while GKOS trades at $92.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas GKOS's P/E ratio is -40.64. In terms of profitability, NVCN's ROE is -1.21%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, NVCN is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs INSP Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, INSP has a market cap of 4.71B. Regarding current trading prices, NVCN is priced at $30.03, while INSP trades at $159.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas INSP's P/E ratio is 72.94. In terms of profitability, NVCN's ROE is -1.21%, compared to INSP's ROE of +0.10%. Regarding short-term risk, NVCN is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs NARI Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, NVCN is priced at $30.03, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas NARI's P/E ratio is -59.24. In terms of profitability, NVCN's ROE is -1.21%, compared to NARI's ROE of -0.18%. Regarding short-term risk, NVCN is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs IRTC Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, IRTC has a market cap of 4.46B. Regarding current trading prices, NVCN is priced at $30.03, while IRTC trades at $139.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas IRTC's P/E ratio is -44.66. In terms of profitability, NVCN's ROE is -1.21%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, NVCN is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs ITGR Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ITGR has a market cap of 4.22B. Regarding current trading prices, NVCN is priced at $30.03, while ITGR trades at $120.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ITGR's P/E ratio is 56.25. In terms of profitability, NVCN's ROE is -1.21%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, NVCN is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs TMDX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, TMDX has a market cap of 4.13B. Regarding current trading prices, NVCN is priced at $30.03, while TMDX trades at $122.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas TMDX's P/E ratio is 114.12. In terms of profitability, NVCN's ROE is -1.21%, compared to TMDX's ROE of +0.18%. Regarding short-term risk, NVCN is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs AXNX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, NVCN is priced at $30.03, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NVCN's ROE is -1.21%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NVCN is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs PRCT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, PRCT has a market cap of 2.93B. Regarding current trading prices, NVCN is priced at $30.03, while PRCT trades at $53.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas PRCT's P/E ratio is -31.38. In terms of profitability, NVCN's ROE is -1.21%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NVCN is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs LIVN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, LIVN has a market cap of 2.40B. Regarding current trading prices, NVCN is priced at $30.03, while LIVN trades at $44.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas LIVN's P/E ratio is -10.83. In terms of profitability, NVCN's ROE is -1.21%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, NVCN is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs NUVA Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, NVCN is priced at $30.03, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NVCN's ROE is -1.21%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NVCN is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs UFPT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, UFPT has a market cap of 1.91B. Regarding current trading prices, NVCN is priced at $30.03, while UFPT trades at $247.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas UFPT's P/E ratio is 30.40. In terms of profitability, NVCN's ROE is -1.21%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, NVCN is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ATEC Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ATEC has a market cap of 1.86B. Regarding current trading prices, NVCN is priced at $30.03, while ATEC trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ATEC's P/E ratio is -11.16. In terms of profitability, NVCN's ROE is -1.21%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, NVCN is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs CNMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CNMD has a market cap of 1.86B. Regarding current trading prices, NVCN is priced at $30.03, while CNMD trades at $60.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CNMD's P/E ratio is 15.76. In terms of profitability, NVCN's ROE is -1.21%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, NVCN is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs TNDM Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, TNDM has a market cap of 1.54B. Regarding current trading prices, NVCN is priced at $30.03, while TNDM trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas TNDM's P/E ratio is -8.29. In terms of profitability, NVCN's ROE is -1.21%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, NVCN is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs HSKA Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, NVCN is priced at $30.03, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NVCN's ROE is -1.21%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NVCN is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs AORT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, AORT has a market cap of 1.23B. Regarding current trading prices, NVCN is priced at $30.03, while AORT trades at $28.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas AORT's P/E ratio is -56.69. In terms of profitability, NVCN's ROE is -1.21%, compared to AORT's ROE of -0.07%. Regarding short-term risk, NVCN is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs AHCO Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, AHCO has a market cap of 1.22B. Regarding current trading prices, NVCN is priced at $30.03, while AHCO trades at $9.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas AHCO's P/E ratio is 15.56. In terms of profitability, NVCN's ROE is -1.21%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, NVCN is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs SILK Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, NVCN is priced at $30.03, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SILK's P/E ratio is -18.96. In terms of profitability, NVCN's ROE is -1.21%, compared to SILK's ROE of -0.37%. Regarding short-term risk, NVCN is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs FNA Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, NVCN is priced at $30.03, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas FNA's P/E ratio is -19.83. In terms of profitability, NVCN's ROE is -1.21%, compared to FNA's ROE of -0.36%. Regarding short-term risk, NVCN is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs IART Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, IART has a market cap of 1.05B. Regarding current trading prices, NVCN is priced at $30.03, while IART trades at $13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas IART's P/E ratio is -35.55. In terms of profitability, NVCN's ROE is -1.21%, compared to IART's ROE of -0.03%. Regarding short-term risk, NVCN is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs INMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, INMD has a market cap of 1.04B. Regarding current trading prices, NVCN is priced at $30.03, while INMD trades at $14.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas INMD's P/E ratio is 6.69. In terms of profitability, NVCN's ROE is -1.21%, compared to INMD's ROE of +0.25%. Regarding short-term risk, NVCN is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ESTA Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ESTA has a market cap of 1.01B. Regarding current trading prices, NVCN is priced at $30.03, while ESTA trades at $34.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ESTA's P/E ratio is -11.65. In terms of profitability, NVCN's ROE is -1.21%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, NVCN is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs CSII Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, NVCN is priced at $30.03, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CSII's P/E ratio is -20.83. In terms of profitability, NVCN's ROE is -1.21%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NVCN is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs CRY Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, NVCN is priced at $30.03, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CRY's P/E ratio is 425.71. In terms of profitability, NVCN's ROE is -1.21%, compared to CRY's ROE of -0.07%. Regarding short-term risk, NVCN is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs SIBN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SIBN has a market cap of 719.58M. Regarding current trading prices, NVCN is priced at $30.03, while SIBN trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SIBN's P/E ratio is -22.60. In terms of profitability, NVCN's ROE is -1.21%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, NVCN is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs IRMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, IRMD has a market cap of 676.82M. Regarding current trading prices, NVCN is priced at $30.03, while IRMD trades at $53.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas IRMD's P/E ratio is 34.34. In terms of profitability, NVCN's ROE is -1.21%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NVCN is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs CBLL Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CBLL has a market cap of 599.97M. Regarding current trading prices, NVCN is priced at $30.03, while CBLL trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CBLL's P/E ratio is -4.90. In terms of profitability, NVCN's ROE is -1.21%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, NVCN is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs AVNS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, AVNS has a market cap of 587.76M. Regarding current trading prices, NVCN is priced at $30.03, while AVNS trades at $12.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas AVNS's P/E ratio is -1.54. In terms of profitability, NVCN's ROE is -1.21%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, NVCN is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BFLY Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BFLY has a market cap of 587.31M. Regarding current trading prices, NVCN is priced at $30.03, while BFLY trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BFLY's P/E ratio is -7.92. In terms of profitability, NVCN's ROE is -1.21%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, NVCN is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs APEN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, NVCN is priced at $30.03, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas APEN's P/E ratio is -9.43. In terms of profitability, NVCN's ROE is -1.21%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NVCN is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs KIDS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, KIDS has a market cap of 574.89M. Regarding current trading prices, NVCN is priced at $30.03, while KIDS trades at $23.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas KIDS's P/E ratio is -14.15. In terms of profitability, NVCN's ROE is -1.21%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NVCN is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BFLY-WT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BFLY-WT has a market cap of 557.02M. Regarding current trading prices, NVCN is priced at $30.03, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, NVCN's ROE is -1.21%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, NVCN is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs RXST Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, RXST has a market cap of 536.41M. Regarding current trading prices, NVCN is priced at $30.03, while RXST trades at $13.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas RXST's P/E ratio is -18.59. In terms of profitability, NVCN's ROE is -1.21%, compared to RXST's ROE of -0.10%. Regarding short-term risk, NVCN is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs AXGN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, AXGN has a market cap of 495.52M. Regarding current trading prices, NVCN is priced at $30.03, while AXGN trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas AXGN's P/E ratio is -47.30. In terms of profitability, NVCN's ROE is -1.21%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, NVCN is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs OFIX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, OFIX has a market cap of 489.37M. Regarding current trading prices, NVCN is priced at $30.03, while OFIX trades at $12.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas OFIX's P/E ratio is -3.78. In terms of profitability, NVCN's ROE is -1.21%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, NVCN is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs TMCI Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, TMCI has a market cap of 439.08M. Regarding current trading prices, NVCN is priced at $30.03, while TMCI trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas TMCI's P/E ratio is -7.76. In terms of profitability, NVCN's ROE is -1.21%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, NVCN is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BVS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BVS has a market cap of 433.98M. Regarding current trading prices, NVCN is priced at $30.03, while BVS trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BVS's P/E ratio is -12.58. In terms of profitability, NVCN's ROE is -1.21%, compared to BVS's ROE of -0.21%. Regarding short-term risk, NVCN is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs NPCE Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, NPCE has a market cap of 424.15M. Regarding current trading prices, NVCN is priced at $30.03, while NPCE trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas NPCE's P/E ratio is -13.92. In terms of profitability, NVCN's ROE is -1.21%, compared to NPCE's ROE of -2.58%. Regarding short-term risk, NVCN is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs SRDX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SRDX has a market cap of 397.81M. Regarding current trading prices, NVCN is priced at $30.03, while SRDX trades at $27.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SRDX's P/E ratio is -19.87. In terms of profitability, NVCN's ROE is -1.21%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, NVCN is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs CLPT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CLPT has a market cap of 397.31M. Regarding current trading prices, NVCN is priced at $30.03, while CLPT trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CLPT's P/E ratio is -20.29. In terms of profitability, NVCN's ROE is -1.21%, compared to CLPT's ROE of -0.62%. Regarding short-term risk, NVCN is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs SENS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SENS has a market cap of 386.23M. Regarding current trading prices, NVCN is priced at $30.03, while SENS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SENS's P/E ratio is -4.92. In terms of profitability, NVCN's ROE is -1.21%, compared to SENS's ROE of -7.46%. Regarding short-term risk, NVCN is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs CTKB Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CTKB has a market cap of 377.44M. Regarding current trading prices, NVCN is priced at $30.03, while CTKB trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CTKB's P/E ratio is -59.60. In terms of profitability, NVCN's ROE is -1.21%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, NVCN is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs NNOX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, NNOX has a market cap of 364.08M. Regarding current trading prices, NVCN is priced at $30.03, while NNOX trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas NNOX's P/E ratio is -6.27. In terms of profitability, NVCN's ROE is -1.21%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, NVCN is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs SMLR Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SMLR has a market cap of 352.19M. Regarding current trading prices, NVCN is priced at $30.03, while SMLR trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SMLR's P/E ratio is 7.15. In terms of profitability, NVCN's ROE is -1.21%, compared to SMLR's ROE of +0.35%. Regarding short-term risk, NVCN is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs PACB Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, PACB has a market cap of 345.05M. Regarding current trading prices, NVCN is priced at $30.03, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas PACB's P/E ratio is -0.72. In terms of profitability, NVCN's ROE is -1.21%, compared to PACB's ROE of -1.25%. Regarding short-term risk, NVCN is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs VREX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, VREX has a market cap of 311.25M. Regarding current trading prices, NVCN is priced at $30.03, while VREX trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas VREX's P/E ratio is -6.41. In terms of profitability, NVCN's ROE is -1.21%, compared to VREX's ROE of -0.08%. Regarding short-term risk, NVCN is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs OM Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, OM has a market cap of 305.53M. Regarding current trading prices, NVCN is priced at $30.03, while OM trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas OM's P/E ratio is -0.47. In terms of profitability, NVCN's ROE is -1.21%, compared to OM's ROE of -2.17%. Regarding short-term risk, NVCN is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs VMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, VMD has a market cap of 272.32M. Regarding current trading prices, NVCN is priced at $30.03, while VMD trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas VMD's P/E ratio is 24.61. In terms of profitability, NVCN's ROE is -1.21%, compared to VMD's ROE of +0.09%. Regarding short-term risk, NVCN is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs CERS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CERS has a market cap of 250.42M. Regarding current trading prices, NVCN is priced at $30.03, while CERS trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CERS's P/E ratio is -13.10. In terms of profitability, NVCN's ROE is -1.21%, compared to CERS's ROE of -0.35%. Regarding short-term risk, NVCN is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ZIMV Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ZIMV has a market cap of 248.78M. Regarding current trading prices, NVCN is priced at $30.03, while ZIMV trades at $8.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ZIMV's P/E ratio is -7.24. In terms of profitability, NVCN's ROE is -1.21%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, NVCN is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs MXCT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, MXCT has a market cap of 233.90M. Regarding current trading prices, NVCN is priced at $30.03, while MXCT trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas MXCT's P/E ratio is -5.64. In terms of profitability, NVCN's ROE is -1.21%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, NVCN is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs TCMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, TCMD has a market cap of 229.69M. Regarding current trading prices, NVCN is priced at $30.03, while TCMD trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas TCMD's P/E ratio is 14.97. In terms of profitability, NVCN's ROE is -1.21%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, NVCN is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs NVRO Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, NVCN is priced at $30.03, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NVCN's ROE is -1.21%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NVCN is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs EYES Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, NVCN is priced at $30.03, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas EYES's P/E ratio is N/A. In terms of profitability, NVCN's ROE is -1.21%, compared to EYES's ROE of -0.26%. Regarding short-term risk, NVCN is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ELMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ELMD has a market cap of 195.27M. Regarding current trading prices, NVCN is priced at $30.03, while ELMD trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ELMD's P/E ratio is 30.43. In terms of profitability, NVCN's ROE is -1.21%, compared to ELMD's ROE of +0.16%. Regarding short-term risk, NVCN is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs CATX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CATX has a market cap of 189.94M. Regarding current trading prices, NVCN is priced at $30.03, while CATX trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CATX's P/E ratio is -2.10. In terms of profitability, NVCN's ROE is -1.21%, compared to CATX's ROE of -0.27%. Regarding short-term risk, NVCN is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BWAY Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BWAY has a market cap of 186.83M. Regarding current trading prices, NVCN is priced at $30.03, while BWAY trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BWAY's P/E ratio is 55.00. In terms of profitability, NVCN's ROE is -1.21%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, NVCN is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs RCEL Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, RCEL has a market cap of 185.31M. Regarding current trading prices, NVCN is priced at $30.03, while RCEL trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas RCEL's P/E ratio is -2.93. In terms of profitability, NVCN's ROE is -1.21%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, NVCN is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs BDMD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, BDMD has a market cap of 180.80M. Regarding current trading prices, NVCN is priced at $30.03, while BDMD trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas BDMD's P/E ratio is 14.57. In terms of profitability, NVCN's ROE is -1.21%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, NVCN is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs QTRX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, QTRX has a market cap of 180.13M. Regarding current trading prices, NVCN is priced at $30.03, while QTRX trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas QTRX's P/E ratio is -4.64. In terms of profitability, NVCN's ROE is -1.21%, compared to QTRX's ROE of -0.12%. Regarding short-term risk, NVCN is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ANIK Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ANIK has a market cap of 177.98M. Regarding current trading prices, NVCN is priced at $30.03, while ANIK trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ANIK's P/E ratio is -20.68. In terms of profitability, NVCN's ROE is -1.21%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, NVCN is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs MASS Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, MASS has a market cap of 166.19M. Regarding current trading prices, NVCN is priced at $30.03, while MASS trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas MASS's P/E ratio is -2.19. In terms of profitability, NVCN's ROE is -1.21%, compared to MASS's ROE of -0.13%. Regarding short-term risk, NVCN is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs INGN Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, INGN has a market cap of 165.09M. Regarding current trading prices, NVCN is priced at $30.03, while INGN trades at $6.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas INGN's P/E ratio is -4.04. In terms of profitability, NVCN's ROE is -1.21%, compared to INGN's ROE of -0.15%. Regarding short-term risk, NVCN is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs LNSR Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, LNSR has a market cap of 164.97M. Regarding current trading prices, NVCN is priced at $30.03, while LNSR trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas LNSR's P/E ratio is -5.12. In terms of profitability, NVCN's ROE is -1.21%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, NVCN is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs TLSI Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, TLSI has a market cap of 163.94M. Regarding current trading prices, NVCN is priced at $30.03, while TLSI trades at $5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas TLSI's P/E ratio is -3.87. In terms of profitability, NVCN's ROE is -1.21%, compared to TLSI's ROE of +1.14%. Regarding short-term risk, NVCN is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs AVR Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, AVR has a market cap of 163.53M. Regarding current trading prices, NVCN is priced at $30.03, while AVR trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas AVR's P/E ratio is -2.30. In terms of profitability, NVCN's ROE is -1.21%, compared to AVR's ROE of -4.16%. Regarding short-term risk, NVCN is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs SGHT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, SGHT has a market cap of 157.67M. Regarding current trading prices, NVCN is priced at $30.03, while SGHT trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas SGHT's P/E ratio is -2.96. In terms of profitability, NVCN's ROE is -1.21%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, NVCN is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs CVRX Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, CVRX has a market cap of 141.83M. Regarding current trading prices, NVCN is priced at $30.03, while CVRX trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas CVRX's P/E ratio is -2.05. In terms of profitability, NVCN's ROE is -1.21%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, NVCN is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs RPID Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, RPID has a market cap of 138.50M. Regarding current trading prices, NVCN is priced at $30.03, while RPID trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas RPID's P/E ratio is -2.93. In terms of profitability, NVCN's ROE is -1.21%, compared to RPID's ROE of -0.52%. Regarding short-term risk, NVCN is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs LUNG Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, LUNG has a market cap of 133.45M. Regarding current trading prices, NVCN is priced at $30.03, while LUNG trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas LUNG's P/E ratio is -2.30. In terms of profitability, NVCN's ROE is -1.21%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, NVCN is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs PROF Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, PROF has a market cap of 128.33M. Regarding current trading prices, NVCN is priced at $30.03, while PROF trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas PROF's P/E ratio is -3.81. In terms of profitability, NVCN's ROE is -1.21%, compared to PROF's ROE of -0.62%. Regarding short-term risk, NVCN is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs LUCD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, LUCD has a market cap of 125.41M. Regarding current trading prices, NVCN is priced at $30.03, while LUCD trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas LUCD's P/E ratio is -1.13. In terms of profitability, NVCN's ROE is -1.21%, compared to LUCD's ROE of -4.60%. Regarding short-term risk, NVCN is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs MYO Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, MYO has a market cap of 115.13M. Regarding current trading prices, NVCN is priced at $30.03, while MYO trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas MYO's P/E ratio is -20.00. In terms of profitability, NVCN's ROE is -1.21%, compared to MYO's ROE of -0.45%. Regarding short-term risk, NVCN is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ICAD Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ICAD has a market cap of 107.86M. Regarding current trading prices, NVCN is priced at $30.03, while ICAD trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ICAD's P/E ratio is -18.71. In terms of profitability, NVCN's ROE is -1.21%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NVCN is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs HJLI Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, NVCN is priced at $30.03, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas HJLI's P/E ratio is N/A. In terms of profitability, NVCN's ROE is -1.21%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, NVCN is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs ASXC Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, NVCN is priced at $30.03, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NVCN's ROE is -1.21%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, NVCN is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for NVCN.
NVCN vs MGRM Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, MGRM has a market cap of 91.22M. Regarding current trading prices, NVCN is priced at $30.03, while MGRM trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas MGRM's P/E ratio is -5.07. In terms of profitability, NVCN's ROE is -1.21%, compared to MGRM's ROE of -1.29%. Regarding short-term risk, NVCN is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs OWLT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, OWLT has a market cap of 88.41M. Regarding current trading prices, NVCN is priced at $30.03, while OWLT trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas OWLT's P/E ratio is -3.41. In terms of profitability, NVCN's ROE is -1.21%, compared to OWLT's ROE of +1.37%. Regarding short-term risk, NVCN is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.
NVCN vs XTNT Comparison
NVCN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVCN stands at 82.86M. In comparison, XTNT has a market cap of 83.08M. Regarding current trading prices, NVCN is priced at $30.03, while XTNT trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVCN currently has a P/E ratio of -1.99, whereas XTNT's P/E ratio is -4.98. In terms of profitability, NVCN's ROE is -1.21%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, NVCN is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for NVCN.